A biotechnology company focused on developing precision therapies for cancer and autoimmune diseases using proprietary technology platforms.

Hummingbird Bioscience

Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. 

Sign up for our updates here: https://bit.ly/HMBDNews

Heritas Capital

Amgen Ventures

Mirae Asset Venture Investment

Pureos Bioventures

Seeds Capital

Novo Holdings

Octagon Capital Advisors

Polaris Partners

Droia Ventures

EDBI

Frazier Healthcare Partners

Kon Yew Kwek, BMBCh, DPhil, Senior Vice President of Clinical Development at Hummingbird Bioscience will share our clinical development strategy and progress at the SCRI Clinical Trials Symposium 2024 (30-31 July): https://bit.ly/3xIprzF 

Kon Yew will also participate in a panel discussing the possibilities for biotechs conducting clinical trials in Singapore. 

 31 July 2024 (Day 2)
 Time: 11 am – 12.30 pm 
 
 Organized by the Singapore Clinical Research Institute (SCRI), the two-day event aims to showcase the impact of and opportunities for clinical trials in Singapore. 
 
 #clinicaldevelopment #clinicaltrials #singapore

Hummingbird Bioscience partnered with the Children's Wishing Well to spark children’s interest in biology and conservation. In a visit to Science Centre Singapore last month, volunteers from our team accompanied ~40 children on the “Young Geneticist Trail”, for the children to learn about DNA and genetic inheritance. The children also viewed a screening of the “Jane Goodall – Reasons for Hope” documentary at the Omni-theatre. We hope the children enjoyed their day! 

#csr #scienceeducation #biology

Gary Khoo 邱思贤, VP of CMC at Hummingbird Bioscience will speak at a panel at World ADC Asia (25-27 June, Incheon, South Korea). Gary will share about how we manage our ADC production processes. The panel will discuss supply chain management of ADC components in Asia Pacific, and navigation of European and American markets. If you will be at World ADC Asia, connect with Gary at the panel discussion. 

#worldADC #ADC World ADC Event Series

Hummingbird Bioscience will present its next-generation antibody-drug conjugate capabilities (ADC) at PEGS Boston 2024 (13-17 May). 
 
For the first time, the company will present how its proprietary 4th generation ADC platform overcomes the resistance observed with earlier generation single payload ADCs. The company will also present how its proprietary Rational Antibody Discovery (RAD) platform enables epitope-directed discovery against challenging targets for optimal drug properties. 
 
Read more on the press release: https://bit.ly/3UGUYd0

This is the third year that Hummingbird Bioscience has collaborated with South West Community Development Council and People's Association to give back to the community. On 23rd and 24th February 2024, our CSR committee and volunteers packed and distributed bags of food and necessities to households in Telok Blangah. We hope that our contributions have made a positive impact on the community. 
 
The initiative is part of a larger program (Adopt @ South West) by the South West CDC, to provide well-rounded assistance in the areas of social support & wellness, education & enrichment, and home maintenance & improvement.

The Hummingbird Bioscience team will present our clinical development, CMC, and regulatory capabilities at Clinical Trials Festival Asia and Biologics Manufacturing Asia, at Marina Bay Sands Expo & Convention Centre in Singapore on 20-21 March. 
 
Carlo Polo, Senior Director of Regulatory Science, and Kon Yew Kwek, Senior Vice President of Clinical Development will present regulatory insights on Asia’s clinical trials and our approach to precision oncology. 
 
Gary Khoo, Vice President of CMC, will present the key considerations in developing and manufacturing next generation ADCs. Gary will also be on a panel discussing the Asia biomanufacturing market. 
 
IMAPAC #clinicaldevelopment #regulatoryscience #ADC

msh id	COM:HUMMINGBIRDBIOSCIENCE
symbol	-
name	Hummingbird Bioscience
homepage url	https://hummingbirdbioscience.com
country	SG
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	96
crunchbase url	-
linkedin url	https://www.linkedin.com/company/hummingbird-bioscience
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

HUMM

COM:HUMMINGBIRDBIOSCIENCE

Hummingbird Bioscience

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-